CLOVES syndrome
Overview
CLOVES syndrome is a rare congenital disorder characterized by a combination of vascular anomalies, overgrowth, and other distinctive features. The acronym CLOVES stands for Congenital, Lipomatous, Overgrowth, Vascular malformations, Epidermal nevi, and Skeletal/spinal anomalies. This condition is caused by mutations in the PIK3CA gene, which plays a crucial role in cell growth and division.
Etiology
CLOVES syndrome is caused by somatic mutations in the PIK3CA gene. These mutations lead to the activation of the PI3K-AKT-mTOR pathway, which results in abnormal cell growth and proliferation. The PIK3CA gene is part of the phosphoinositide 3-kinase (PI3K) family, which is involved in various cellular functions, including metabolism, growth, and survival.

Clinical Features
Patients with CLOVES syndrome present with a wide range of clinical features, which can vary significantly in severity. Common manifestations include:
- Vascular malformations: These can include capillary, venous, and lymphatic malformations.
- Lipomatous overgrowth: Abnormal growth of fatty tissue, often asymmetric.
- Epidermal nevi: Skin lesions that are present at birth.
- Skeletal anomalies: These may include scoliosis, limb length discrepancies, and other bone abnormalities.
- Spinal anomalies: Such as tethered cord syndrome.
Diagnosis
The diagnosis of CLOVES syndrome is primarily clinical, based on the presence of characteristic features. Genetic testing can confirm the diagnosis by identifying mutations in the PIK3CA gene. Imaging studies, such as MRI and CT scans, are often used to assess the extent of vascular malformations and overgrowth.
Management
Management of CLOVES syndrome is multidisciplinary and tailored to the individual patient's needs. It may include:
- Surgical intervention to address overgrowth and vascular malformations.
- Sclerotherapy for vascular anomalies.
- Orthopedic management for skeletal deformities.
- Regular monitoring and supportive care.
Prognosis
The prognosis for individuals with CLOVES syndrome varies depending on the severity of the condition and the presence of complications. Early diagnosis and appropriate management can improve outcomes and quality of life.
Related pages
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian